Patent Application
20180112189
The presently disclosed subject matter relates to an in vitro skin equivalent, in particular of animal skin, or of mammalian and/or human skin, and to the use thereof.
The presently disclosed subject matter can be used in particular in the pharmacological, cosmetological and dermatological fields.
In the description below, the references between square brackets ([ ]) refer back to the list of references presented at the end of the text.
The skin is a very complex organ including a very particular stratified structure. It includes three main parts:
It in particular provides a barrier between the external media and the internal medium of many mammals, including in particular human beings. By virtue of this “barrier” function, the skin naturally provides protection for the organism while at the same time providing communication between the organism and the external environment. The skin constitutes the first organ of defense against any attack.
The skin is subjected to many attacks; they can for example be attacks associated with UV rays that can lead to inflammatory reactions/cell modifications responsible for cancers, physical attacks such as burns, scarifications, for example due to blunt objects, chemical attacks, for example associated with chemical products, for example detergents. These various attacks can in particular induce skin disorders capable of modifying the structure of the skin, of altering its coloration, of causing the appearance of skin wounds and/or bringing about skin “aging”.
It is known as a matter of fact that external attacks can lead to structural modifications and/or alter the appearance of the skin, can in particular cause the appearance of signs of skin aging, such as wrinkles, drying of the skin, an alteration in the pigmentation.
It is, moreover, also known that chemical products and/or molecules such as hydroquinone, when they are used at high doses, can induce strong depigmentation, can cause scars, stretch marks, skin cancers or systemic complications, the development of pilosity and can cause beard growth and a disturbance of body odor.
Other elements can be responsible for an alteration of the skin, for example parameters of genetic order and/or parameters associated with systemic endocrine and/or autoimmune disorders. They can in particular be pathological conditions which cause a pigment disorder, such as vitiligo, hypermelanosis, hypomelanosis or a nevus.
Before the commercialization of any product, it may be necessary and important to be able to study and evaluate the possible side effects which might appear and/or to determine the appropriate pharmaceutical forms/concentrations.
There exists, in the related art, skin “models” used in particular to study skin physiology and/or that can be used in tests of compounds in order to determine their activity and/or their possible side effects.
However, the commercially available skin “models” used are products that are fragile both in structural terms and in epidemiological terms. Thus, these products are often small in size in order in particular to avoid any tearing of the product during handling thereof.
There are also in the related art systems/methods for preparing skin substitutes, for example as described in document U.S. Pat. No. 5,755,814, including in particular the culture of cells, in particular of fibroblasts, of a mixture of melanocytes and keratinocytes. However, these systems/methods do not make it possible to obtain a substitute with a structure identical to that of the skin in vivo. In addition, the substitutes obtained by these methods can exhibit or do exhibit parakeratosis, which is a skin differentiation abnormality, corresponding to abnormal maturation of the keratin in the horny layer which does not therefore allow them to be used in the treatment of skin disorders and/or losses of skin substance, as a skin model, etc. Finally, the known systems/methods for preparing skin substitutes use in particular media including compounds which are incompatible with clinical use, for example bovine pituitary extract. Thus, the equivalent substitutes obtained can in particular be used neither in clinical practice nor as a skin model.
There is therefore a real need to find a skin equivalent which overcomes these faults, drawbacks and obstacles of the related art, in particular a skin equivalent including the major constituent cells of the skin and which can be used in order to evaluate the effectiveness/effect on the skin and/or the possible side effects of a compound.
There is also a real need in the related art to find a skin equivalent which can represent/reproduce “pathological” skin, making it possible in particular to evaluate the effectiveness and/or the possible side effects of a candidate compound for the treatment.
In addition, there is a real need in the related art to find a skin equivalent which makes it possible to obtain reliable and reproducible results, in particular of the effectiveness and/or of the possible side effects of a candidate compound for the treatment.
An aspect of the presently disclosed subject matter is specifically to meet this need and address the abovementioned related art problems by providing a skin equivalent which can be obtained by a preparation method including the following steps:
In the presently disclosed subject matter, the term “include” can mean equally, on the one hand, “include”, “contain” or “encompass” and, on the other hand, “constituted of” or “consist of”.
In the presently disclosed subject matter, the dermal substitute obtained according to the method of some embodiments is a complete tissue which reproduces the characteristics of a dermis in vivo, namely which includes macromolecules of protein type, in particular collagen fibers, glycosaminoglycan fibers, proteins and functional fibroblasts.
In the presently disclosed subject matter, the skin equivalent is also referred to as the skin substitute, and the dermal equivalent is also referred to as the dermal substitute.
In the presently disclosed subject matter, the skin equivalent obtained according to the method is advantageously a complete tissue which reproduces the characteristics of a skin in vivo, namely which includes a keratinized pluristratified epithelium including keratinocytes reproducing a stratum basal, a stratum spinosum, a stratum granulosum and a stratum corneum which are histologically normal, and basal melanocytes in contact with a dermal substitute containing functional fibroblasts, via a functional basal lamina.
Advantageously, the skin equivalent includes a basal lamina can consist of in particular of a protein mixture secreted by the cells of the substitute thus forming a dermal-epidermal junction reproducing the characteristics of a skin in vivo.
In the presently disclosed subject matter, the fibroblasts, melanocytes and keratinocytes that can be used in the method which makes it possible to obtain the skin equivalent can be all or most fibroblasts, melanocytes and keratinocytes known to those with ordinary skill in the art. They can for example be fibroblasts, melanocytes and/or keratinocytes obtained from cell banks, for example originating from the Collection Nationale de Culture de Microorganisme [French National Collection of Microorganism Cultures] (CNCM) of the Institut Pasteur, 25 rue du Docteur Roux, F-75724 Paris Cedex 15. They can also be commercially available fibroblasts, melanocytes and/or keratinocytes, for example the cells sold by the company Thermofischer Scientific, the company CellnTec, or the company Promocell, the company American Type Culture Collection (ATCC), the company LGC Standards S.a.r.l. They can also be fibroblasts, melanocytes and/or keratinocytes isolated from a biological sample from an animal, including a mammal and/or from a human being, isolated beforehand. The fibroblasts, melanocytes and/or keratinocytes can be fibroblasts, melanocytes and/or keratinocytes isolated independently from a biopsy or several biopsies. The fibroblasts, melanocytes and/or keratinocytes can be isolated independently from a biopsy or several biopsies from an individual, such as a mammal and/or a human being, for the purpose of a graft of the skin substitute onto the patient. They can independently be fibroblasts, melanocytes and/or keratinocytes which are autologous or heterologous with respect to an individual.
The fibroblasts, melanocytes and/or keratinocytes can be isolated independently from a biopsy or several biopsies originating, for example, from Caucasian, Asian or African skin, from various anatomical sites, for example from the back, face, breast, back of the hands, palms of a human being.
They can independently be fibroblasts, melanocytes and/or keratinocytes independently isolated from skin biopsies, for example, from a human being. They can, for example, be fibroblasts, melanocytes and/or keratinocytes independently isolated from healthy skin or skin having at least one skin pathology. They can, for example, be fibroblasts, melanocytes and/or keratinocytes independently isolated from skin having, for example, age spots (actinic lentigo), melasma, vitiligo, nevus, melanoma, xeroderma pigmentosum. They can also be fibroblasts, melanocytes and/or keratinocytes independently isolated from skin biopsies resulting from mammals having genetic pathologies, for example from a skin biopsy resulting from a human being suffering from progeria, restrictive dermopathy, epidermolysis bullosa or ichthyosis. They can also be fibroblasts, melanocytes and/or keratinocytes independently isolated from skin biopsies resulting from mammals under pharmacological treatment; for example, they can be fibroblasts, melanocytes and/or keratinocytes isolated from a biopsy of a human being under treatment against leukemia or of a human being under dermatological treatment, for example for the treatment of acne or juvenile acne.
They can also be fibroblasts, melanocytes and/or keratinocytes which have been independently genetically modified, for example with retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs). They can for example be fibroblasts, melanocytes and/or keratinocytes independently overexpressing at least one protein, for example a protein chosen from collagen VII, keratins 5, 14, catalase and SIRT6, and/or underexpressing at least one protein, for example via the small hairpin RNA (shRNA) or small interfering RNA (siRNA) technique, for example collagen VII, HIF1 or CCN3. They can for example be fibroblasts, melanocytes and/or keratinocytes which have been independently genetically modified as described in Pendaries V et al., JID 2012 [1]; Petek L M et al. Mol ther 2010 [2]. They can for example be fibroblasts, melanocytes and/or keratinocytes which can or can not have been independently genetically modified, for example the Ker-CT cell identified under the reference ATCC CRL-4048, or the TeICOFS02MA cell identified under the reference ATCC CRL-4005.
They can also be fibroblasts, melanocytes and/or keratinocytes derived from a cell line, for example the HaCaT keratinocyte line, or the WS1 fibroblast line.
They can also be fibroblasts, melanocytes and/or keratinocytes independently obtained from adult stem cells, from pluripotent stem cells induced, for example, by maintaining the adult stem cells, and/or from pluripotent stem cells induced via, for example, the introduction of Oct3/4, Sox 2, KLF4 or c-Myc genes and then differentiated by factor cocktails, for example retinoic acid and/or BMP-4, into a cell line. They can also be adult stem cells and/or pluripotent stem cells induced by non-viral techniques based on the use of nanoparticles, for example arginine-terminated polyamidoamine nanoparticles. Those with ordinary skill in the art, by virtue of their general knowledge, will be able to choose the method and/or the cells. They can for example be fibroblasts, melanocytes and/or keratinocytes obtained by the method described in Kogut et al. Methods Mol Biol 2014 [3], in Ohta et al., Methods Mol Biol, 2013 [4], and/or in Revilla et al., J Tissue Eng Regen Med, 2015 [5].
In the presently disclosed subject matter, the term “fibroblast culture medium M1” is intended to mean any medium known to those with ordinary skill in the art that are suitable for the culture of fibroblasts. It can for example be a commercially available medium, for example a Dulbecco's modified Eagle's minimal essential medium (DMEM) sold by the company Gibco, including in particular a mixture of amino acids, of vitamins, of inorganic salts of sugars, for example glucose, or a Fibrolife medium sold by the company Cell Systems.
In the presently disclosed subject matter, the medium M1 can also include supplements, in particular fetal calf serum (FCS).
In the presently disclosed subject matter, the medium M1 can for example include from 5% to 15% by weight, from 7.5 to 12.5% by weight, 10% by weight of fetal calf serum (FCS) relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M1 can include at least one antifungal and/or antibiotic compound. This can for example be any antifungal and/or antibiotic compound known to those with ordinary skill in the art and/or commercially available. It can for example be at least one antifungal compound chosen from the group including amphotericin B, ketoconazole and a mixture thereof. It can for example be at least one antibiotic compound chosen from the group including penicillin, streptomycin, ciprofloxacin and a mixture thereof.
In the presently disclosed subject matter, the medium M1 can include from 0.1% to 10% by weight, from 0.5% to 5% by weight, 1% by weight of antifungal agent relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M1 can include from 0.1% to 10% by weight, from 0.5% to 5% by weight, 1% by weight of antibiotics relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M1 and/or all or most of the constituents thereof can be of clinical grade.
The term “of clinical grade” denotes in the presently disclosed subject matter the fact that the component or the medium has been recognized by the relevant authority as being suitable for use clinically on a given territory. Advantageously in the presently disclosed subject matter, when the medium is of clinical grade, it does not include bovine pituitary extract.
In the presently disclosed subject matter, the fibroblast culture step a. can be carried out at a temperature included from 30 to 40° C., from 35 to 39° C., or equal to 37° C.
In the presently disclosed subject matter, the fibroblast culture time of step a. can be included from 5 to 21 days, from 5 to 15 days, or from 8 to 15 days.
In the presently disclosed subject matter, the fibroblast culture time of step a. can be carried out under a controlled atmosphere including from 5% to 10% of CO2, for example under an atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, the fibroblast culture step a. can be carried out in an incubator at a temperature from 30 to 40° C., from 32 to 40° C., or equal to 37° C. and under a controlled atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, the fibroblast culture step a. can be carried out in any suitable culture container known to those with ordinary skill in the art. It can be a petri dish, or a culture flask with a capacity of 25, 75 or 175 cm2.
In the presently disclosed subject matter, the fibroblasts obtained by culture according to step a. can form a layer of cells at confluence in the culture container. For example, the fibroblasts can be at 70% to 100% confluence, for example, at 100% confluence.
In the presently disclosed subject matter, when the culture according to step a. corresponds to a layer of cells optionally at confluence, the method can also include:
In the presently disclosed subject matter, in step a′, the removal of the culture medium can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the medium, or turning the container upside-down in order to remove the culture medium.
In the presently disclosed subject matter, in step a′, the rinsing of the cells can be carried out by any method known to those with ordinary skill in the art, for example by dipping, sprinkling, or incubation of the cells in a rinsing solution.
In the presently disclosed subject matter, the term “rinsing solution” is intended to mean any solution for rinsing cells that is known to those with ordinary skill in the art. It can for example be an HBSS (Hank's Balanced Salt Solution) buffer solution at a pH included from 7.2 to 7.4.
It can also be a commercially available buffer solution, for example a phosphate buffered saline (PBS), or a Hank's balanced solution sold respectively by the company Gibco, Sigma Aldrich or Lonza.
In the presently disclosed subject matter, in step a′, the removal of the rinsing solution can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the rinsing solution, or turning the container upside-down in order to remove the rinsing solution.
In the presently disclosed subject matter, the trypsinization step a″ can be carried out by immersion of the cells in a buffer solution (BS) including trypsin, followed by the addition of fetal calf serum (FCS) in order to stop the enzymatic reaction.
In the presently disclosed subject matter, the buffer solution (BS) can be any buffer solution known to those with ordinary skill in the art that can be used in a trypsinization method. It can for example be a phosphate buffered saline (PBS), or a Hank's balanced solution sold respectively by the company Gibco, Sigma Aldrich or Lonza.
In the presently disclosed subject matter, the amount of trypsin added to the buffer solution (BS) can be between 0.01% and 0.05% by weight relative to the total weight.
In the presently disclosed subject matter, the incubation time in the buffer solution including trypsin before addition of FCS to the buffer solution (BS) can be between 2 and 10 min.
According to some embodiments, the amount of FCS added to the buffer solution (BS) can be included from 5% to 20% by volume relative to the total volume.
In the presently disclosed subject matter, the pelleting step a″′ can be carried out by any method known to those with ordinary skill in the art. It can for example be a sedimentation or a centrifugation at a speed of 800 to 1400 revolutions per minute, for example equal to 1200 revolutions per minute.
In the presently disclosed subject matter, the centrifugation step a″′ can be carried out for a period of 4 to 10 min, for example equal to 5 minutes.
In the presently disclosed subject matter, the centrifugation step a″′ can be carried out by any device known to those with ordinary skill in the art. It can for example be a rotary centrifuge sold by the company Eppendorf or Jouan.
In the presently disclosed subject matter, the term “matrix including collagen” is intended to mean any matrix including collagen that is known to those with ordinary skill in the art and that can be seeded with cells. It can for example be a collagen matrix corresponding to a non-taut type I collagen gel, not imposing any preferential organization of the fibroblasts, as described in Bell et al., 1979 [6]. It can for example be a matrix with a density/concentration of collagen, for example, of type I collagen, with a surface area of from 25 to 500 cm2. It can for example be a matrix including commercially available collagen, for example it can be a matrix including collagen sold by the company Integra.
Advantageously, the matrix including collagen can be a dermal regeneration matrix. The dermal regeneration matrix can in particular be chosen from the matrices sold under the names Integra (registered trademark) and Matriderm (registered trademark) by the companies Integra Life Science Corporation and MedSkin Solutions Dr. Suwelack A G respectively. Advantageously, and contrary to the other matrices including collagen, the dermal regeneration matrices such as those mentioned above are already modeled, thereby promoting reconstruction of the skin equivalent.
In one embodiment, the matrix including collagen can be a matrix including crosslinked collagen and at least one glycosaminoglycan, for example chondroitin 6-sulfate. It can for example be the Integra matrix (registered trademark) sold by the company Integralife Sciences and/or the matrix obtained according to the method described in the document Boyce S T et al., 1988 [7].
In another embodiment, the matrix including collagen can be a matrix including fibers of native-structure collagen and of elastin. The term “fibers of native-structure collagen” is intended to mean in particular fibers that have not been chemically crosslinked. The matrix can for example be the Matriderm matrix sold by the company MedSkin Solutions Dr. Suwelack A G and/or the matrix obtained according to the method described in the document Hafemann et al., Burns 1999 [8].
In the presently disclosed subject matter, the thickness of the matrix including collagen can be from 1.0 to 3.0 mm (limits included) before seeding with the fibroblasts. In one particular embodiment, the thickness of the matrix including collagen can be strictly greater than 1.0 mm before seeding with the fibroblasts.
In the presently disclosed subject matter, the seeding of step b. can be carried out by any method known to those with ordinary skill in the art. It can for example be an application, for example by sprinkling a culture medium including the fibroblasts onto the matrix, by deposition by subculturing the cells on the matrix, by pouring of a culture medium including the cells in suspension, or by 3D printing for example as described in Wonhye Lee et al. “Multi-layered culture of human skin fibroblasts and keratinocytes through three-dimensional freeform fabrication.” Biomaterials, 2009, March; 30(8):1587-95 [7].
In the presently disclosed subject matter, when step a. includes step a″, the method of some embodiments can include, before the seeding step b., a step b1 of resuspension of the centrifuged cells in the medium M1.
In the presently disclosed subject matter, the seeding of step b. of a collagen matrix can be carried out at a density of from 20 000 to 50 000 fibroblasts/cm2, preferably of 30 000 fibroblasts/cm2 of surface area of the matrix including collagen. In one particular embodiment, the fibroblast density can be strictly less than 50 000 fibroblasts/cm2 of matrix including collagen.
In the presently disclosed subject matter, the fibroblast culture medium M2 can be any medium known to those with ordinary skill in the art suitable for the culture of fibroblasts. It can for example be a commercially available medium, for example a Dulbecco's Modified Eagle's minimal essential medium (DMEM) including in particular a mixture of amino acids, of vitamins, of inorganic salts of sugars, for example, glucose.
In the presently disclosed subject matter, the medium M1 can also include supplements, in particular fetal calf serum (FCS).
In the presently disclosed subject matter, the medium M2 can include from 5 to 15% by weight, from 7.5% to 12.5% by weight, or 10% by weight of fetal calf serum (FCS) relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M2 can include at least one antifungal and/or antibiotic compound. It can for example be any antifungal and/or antibiotic compound known to those with ordinary skill in the art and/or commercially available. It can for example be at least one antifungal compound chosen from the group including amphotericin B, ketoconazole or a mixture thereof. It can for example be at least one antibiotic compound chosen from the group including penicillin, streptomycin, ciprofloxacin and a mixture thereof.
In the presently disclosed subject matter, the medium M2 can include from 0.1% to 10% by weight, from 0.5% to 5% by weight, or 1% by weight of antifungal agent relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M2 can include from 0.1% to 10% by weight, from 0.5% to 5% by weight, or an amount equal to 1% by weight of antibiotics relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M2 can also include ascorbic acid or ascorbate. For example, the medium M2 can include ascorbic acid or ascorbate at a concentration of from 20 to 60 mg·mL−1, for example from 30 to 55 mg·mL−1, or equal to 50 mg·mL−1.
Advantageously, the ascorbic acid makes it possible in particular to promote remodeling of the matrix including collagen by stimulating collagen synthesis by the fibroblasts.
In the presently disclosed subject matter, the medium M2 and/or all or most of the constituents thereof can be of clinical grade.
In the presently disclosed subject matter, the fibroblast culture step c. can be carried out at a temperature included from 30 to 40° C., from 35 to 39° C., or equal to 37° C.
In the presently disclosed subject matter, the fibroblast culture time of step c. can be from 5 to 12 days, or from 7 to 10 days.
In the presently disclosed subject matter, the fibroblast culture step c. can be carried out under a controlled atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, step c. of culture of the fibroblasts seeded in the matrix including collagen can include:
In this embodiment, the fibroblast culture medium M21 corresponds to the medium M2 as defined above including neither ascorbic acid nor ascorbate. In the presently disclosed subject matter, the medium M21 and/or all or most of the constituents thereof can be of clinical grade.
In this embodiment, the fibroblast culture medium M22 corresponds to the medium M2 as defined above including ascorbic acid or an ascorbate. In the presently disclosed subject matter, the medium M22 and/or all or most of the constituents thereof can be of clinical grade.
In the presently disclosed subject matter, the culture step c′. can be carried out at a temperature included from 30 to 40° C., from 35 to 39° C., or equal to 37° C.
In the presently disclosed subject matter, the culture time of step c′. can be from 19 to 27 hours, for example 24 hours.
In the presently disclosed subject matter, the culture step c″. can be carried out at a temperature included from 30 to 40° C., from 35 to 39° C., or equal to 37° C.
In the presently disclosed subject matter, the culture time of step c″. can be from 5 to 12 days, or equal to 7 days.
The present disclosure also demonstrates that the matrix and the cultured fibroblasts obtained in step c. form a structure corresponding to a dermal substitute.
Advantageously, the culture step c′ corresponds to a step of adhesion and of colonization of the matrix by the fibroblasts and step c″ advantageously allowing remodeling of the matrix including the fibroblasts in order to form a dermal substitute. In particular, the succession of steps c′ and c″ with the use respectively of the media M21 and M22 will advantageously make it possible to form a dermal substitute in which the fibroblasts will not proliferate, but colonize the matrix including collagen while at the same time advantageously allowing collagen production by the fibroblasts themselves, thus allowing remodeling of the dermis.
In other words, the product obtained at the end of step c. can be advantageously used as a dermal substitute. In particular, this product includes all or most the physicochemical characteristics of the dermis from which the fibroblasts can be derived.
In the presently disclosed subject matter, the melanocyte culture step d. can be carried out in any suitable culture container known to those with ordinary skill in the art. It can be a petri dish, or a culture flask with a capacity of 25 to 75 cm2, of 25, of 75 of 125 cm2.
In the presently disclosed subject matter, the melanocyte culture medium M3 can be any medium known to those with ordinary skill in the art that is suitable for the culture of melanocytes. It can for example be a commercially available medium, for example a commercially available medium under the reference “Melanocyte Medium M2”, “MBM” sold by the company Promocell, or in an MCDB 153 medium sold by the company Sigma-Aldrich including in particular a mixture of amino acids, of vitamins, of inorganic salts of sugars, for example glucose, as represented in table 3 below:
It can also be a modified commercially available medium, for example the MCDB153 medium also including supplementary amino acids, for example tyrosine, methionine or a mixture thereof, additional inorganic salts, for example sodium bicarbonate (NaHCO3).
In the presently disclosed subject matter, the medium M3 can also include at least one supplement chosen from bovine pituitary extract (BPE), insulin, penicillin-streptomycin (PS), hydrocortisone, horse serum, calf serum, basic fibroblast growth factor (bFGF), granulocyte macrophage colony stimulating factor (GM-CSF), SCF or any mixture thereof.
In the presently disclosed subject matter, the medium M3 can include from 0.1% to 10% by weight, from 0.5 to 5% by weight, or 1% by weight of penicillin-streptomycin (PS) relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M3 can include a hydrocortisone concentration of from 1.25 to 1.60 μM, from 1.40 to 1.55 μM, or 1.45 μM.
In the presently disclosed subject matter, the medium M3 can include a bovine pituitary extract (BPE) concentration of from 100 to 160 μg·mL−1, from 110 to 150 μg·mL−1, or equal to 140 μg·mL−1.
In the presently disclosed subject matter, the medium M3 can include an insulin concentration of from 15 to 25 μg·mL−1, or equal to 20 μg·mL−1.
In the presently disclosed subject matter, the medium M3 can include a GM-CSF concentration of from 0.01 to 0.2 μg·mL−1, from 0.01 to 0.1 μg·mL−1, or equal to 0.01 μg·mL−1.
In the presently disclosed subject matter, the medium M3 can include an SCF concentration of from 0.004 to 0.2 μg·mL−1, from 0.01 to 0.15 μg·mL−1, or equal to 0.05 μg·mL−1.
In the presently disclosed subject matter, the medium M3 can include a bFGF concentration of from 0.1 to 10 ng·mL−1, from 0.5 to 5 ng·mL−1, from 0.8 to 2 ng·mL−1, or equal to 1 ng·mL−1.
In the presently disclosed subject matter, the medium M3 can include from 1% to 5% by weight, from 2% to 4% by weight, or 3% by weight of horse or calf serum relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M3 and/or all or most of the constituents thereof can be of clinical grade.
In the presently disclosed subject matter, the melanocyte culture step d. can be carried out at an ambient temperature, for example at a temperature of 30 to 40° C., for example equal to 37° C.
In the presently disclosed subject matter, the culture time of step d. can be from 15 to 28 days.
In the presently disclosed subject matter, the melanocyte culture of step d. can be carried out under a controlled atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, the melanocytes obtained by culture according to step d. can form a cell layer at confluence in the culture container. For example, the melanocytes can form a cell layer of 50% to 100% confluence.
According to some embodiments, when the culture according to step d. corresponds to a cell layer optionally at confluence, the method can also include:
In the presently disclosed subject matter, in step d′, the removal of the culture medium can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the medium, or turning the container upside-down in order to remove the culture medium.
In the presently disclosed subject matter, in step d′, the rinsing of the cells can be carried out by any method known to those with ordinary skill in the art, for example by sprinkling, or dipping the cells in a rinsing solution.
In the presently disclosed subject matter, the term “melanocyte rinsing solution” is intended to mean any melanocyte rinsing solution known to those with ordinary skill in the art. It can for example be an HBSS buffer solution, for example the solution described in table 2 above, or phosphate buffered saline (PBS) at a pH included from 7.2 to 7.4. It can also be a commercially available buffer solution, for example a phosphate buffered saline (PBS), or a Hank's balanced solution sold respectively by the company Gibco, Sigma Aldrich or Lonza.
In the presently disclosed subject matter, in step d′, the removal of the rinsing solution can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the rinsing solution, or turning the container upside-down in order to remove the rinsing solution.
According to some embodiments, the trypsinization step d″ can be carried out by immersion of the cells in a buffer solution (BS) including trypsin, followed by the addition of fetal calf serum (FCS) in order to stop the enzymatic reaction.
According to some embodiments, the buffer solution (BS) can be a buffer solution as defined above.
According to some embodiments, the amount of trypsin added to the buffer solution (BS) can be from 0.01% to 0.05% by weight relative to the total weight.
According to some embodiments, the trypsin incubation time before addition of the FCS to the buffer solution can be from 2 to 5 min.
In the presently disclosed subject matter, the amount of FCS added to the solution (BS) can be included from 5% to 20% by volume relative to the total volume.
According to some embodiments, the pelleting step d″′ can be carried out by sedimentation, by centrifugation by any method known to those with ordinary skill in the art. It can for example be centrifugation at a speed of from 800 to 1200 revolutions per minute.
In the presently disclosed subject matter, the centrifugation step d″′ can be carried out for a period of from 5 to 10 min.
In the presently disclosed subject matter, the centrifugation step d″′ can be carried out by any device known to those with ordinary skill in the art. It can for example be a rotary centrifuge sold by the company Eppendorf or Jouan.
In the presently disclosed subject matter, the centrifugation step d″′ makes it possible to sediment the cells in order to separate them from the medium. Those with ordinary skill in the art, by virtue of the general knowledge, will know how to adapt/modify the centrifugation step d′″ using any known technique which makes it possible to sediment cells in a medium.
In the presently disclosed subject matter, the keratinocyte culture step e. can be carried out in any suitable culture container known to those with ordinary skill in the art. It can be a petri dish, or a culture flask with a capacity of from 25 to 75 cm2, of 25, of 75 or of 125 cm2.
In the presently disclosed subject matter, the keratinocyte culture medium M4 can be any medium known to those with ordinary skill in the art that is suitable for the culture of keratinocytes. It can for example be a commercially available medium, for example a KSFM medium sold by the company Life-Technology, KGM sold by the company Lonza, or Provitro in an MCDB 153 medium sold by the company Sigma-Aldrich including in particular a mixture of amino acids, of vitamins, of inorganic salts of sugars, for example glucose. It can also be a modified commercially available medium, for example the MCDB153 medium including a sodium chloride concentration of 0.100 to 0.110 M/l, for example of 0.104 M/l, a Hepes concentration of 2 to 3×10−2M/I, for example of 2.29 ×10−2M/I, a sodium bicarbonate concentration of 1.10 ×10−2M/I to 1.25 ×10−2M/I, for example of 1.19 ×10−2M/I, and including a concentration of arginine, histidine, isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, tyrosine, valine and choline which is double that of the concentrations of the unmodified MCDB153 medium.
In the presently disclosed subject matter, the medium M4 can also include supplements chosen from growth factors, for example epithelial growth factor (EGF), bovine pituitary extract (BPE), insulin, penicillin-streptomycin (PS), hydrocortisone or any mixture thereof. Advantageously, the medium M4 can include supplements of clinical grade. They can for example be supplements chosen from growth factors, for example epithelial growth factor (EGF), insulin, penicillin-streptomycin (PS), hydrocortisone or any mixture thereof.
In the presently disclosed subject matter, the medium M4 can include for example from 0.5% to 5% by weight, from 0.75% to 3% by weight, or 1% by weight of penicillin-streptomycin (PS) relative to the total weight of the medium.
In the presently disclosed subject matter, the medium M4 can include a hydrocortisone concentration of from 1.25 to 1.60 μM, from 1.40 to 1.55 μM, or of 1.45 μM.
In the presently disclosed subject matter, the medium M4 can include a bovine pituitary extract (BPE) concentration of from 50 to 90 μg·mL−1, from 60 to 80 μg·mL−1, or of 70 μg·mL−1.
In the presently disclosed subject matter, the medium M4 can include an insulin concentration of from 3 to 8 μg·mL−1, for example equal to 5 μg·mL−1.
In the presently disclosed subject matter, the medium M4 can include an epithelial growth factor (EGF) concentration of from 5 to 15 ng·mL−1, from 6.5 to 13 ng·mL−1, or equal to 10 ng·mL−1.
In the presently disclosed subject matter, the medium M4 and/or all or most of the constituents thereof can be of clinical grade.
In the presently disclosed subject matter, the keratinocyte culture step e. can be carried out at a temperature of 25 to 39° C., for example equal to 37° C.
In the presently disclosed subject matter, the culture time of step e. can be included from 15 to 28 days.
In the presently disclosed subject matter, the keratinocyte culture of step e. can be carried out under a controlled atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, the keratinocytes obtained by a culture according to step e. can form a monolayer of cells in the culture container. It can for example be a monolayer of cells that is close to confluence, for example from 50% to 80% confluence in the culture container.
In the presently disclosed subject matter, when the culture according to step e. corresponds to a monolayer of cells that is close to confluence, preferably from 50% to 80% confluence, the method can also include:
In the presently disclosed subject matter, in step e′, the removal of the culture medium can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the medium, or turning the container upside-down in order to remove the culture medium.
In the presently disclosed subject matter, in step e′, the rinsing of the cells can be carried out by any method known to those with ordinary skill in the art, for example by dipping, sprinkling, or incubation of the cells in a keratinocyte rinsing solution.
In the presently disclosed subject matter, the term “keratinocyte rinsing solution” is intended to mean any keratinocyte rinsing solution known to those with ordinary skill in the art. It can for example be a PBS buffer solution or HBSS buffer solution, for example as described in table 2 above, at a pH included from 7.2 to 7.4. It can also be a commercially available buffer solution, for example a phosphate buffered saline (PBS), or a Hank's balanced solution sold respectively by the company Gibco, Sigma Aldrich or Lonza.
In the presently disclosed subject matter, in step e′, the removal of the keratinocyte rinsing solution can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be suctioning of the keratinocyte rinsing solution, or turning the container upside-down in order to remove the keratinocyte rinsing solution.
In the presently disclosed subject matter, the trypsinization step e″ can be carried out by immersion of the cells in a solution (S) including trypsin, followed by the addition of fetal calf serum (FCS) in order to stop the enzymatic reaction.
In the presently disclosed subject matter, the amount of trypsin added to the solution (S) can be included from 0.01% to 0.05% relative to the total weight of the solution.
In the presently disclosed subject matter, the trypsin incubation time before addition of the FCS to the medium can be included from 5 to 10 min.
In the presently disclosed subject matter, the amount of FCS added to the solution (S) can be included from 5% to 20% by weight relative to the total weight of the solution.
In the presently disclosed subject matter, the centrifugation step e″′ can be carried out by any method known to those with ordinary skill in the art. It can for example be centrifugation at a speed of 800 to 1200 revolutions per minute.
In the presently disclosed subject matter, the centrifugation step e″′ can be carried out for a period of 5 to 10 min.
In the presently disclosed subject matter, the centrifugation step e″′ can be carried out by using any device known to those with ordinary skill in the art. It can for example be a rotary centrifuge sold by the company Eppendorf or Jouan.
In the presently disclosed subject matter, step f. of mixing melanocytes obtained in step d. with keratinocytes obtained in step e. can be carried out by any suitable method known to those with ordinary skill in the art. It can for example be mixing of cells with stirring in a culture medium.
In the presently disclosed subject matter, the mixing of melanocytes and keratinocytes of step f. can be carried out with a melanocytes/keratinocytes ratio by number of 1/20 to 1/15, or equal to 1/19.
Advantageously, the present disclosure demonstrates, surprisingly, that when the mixing of melanocytes and keratinocytes is carried out with a melanocytes/keratinocytes ratio of 1/20 to 1/15, preferably equal to 1/19, the skin substitute or skin equivalent obtained has structural/biological characteristics identical to those of a skin in vivo.
In one embodiment, the mixing of melanocytes and keratinocytes of step f is carried out with a melanocytes/keratinocytes ratio by number of 1/20 to 1/15, or equal to 1/19, and the matrix including collagen is a dermal regeneration matrix as defined above.
In the presently disclosed subject matter, the seeding of the dermal substitute of step g. can be carried out by any method known to those with ordinary skill in the art. It can for example be an application, for example by sprinkling of the culture medium including a mixture of melanocytes and keratinocytes obtained in step f., by deposition by subculturing the cells on the dermal substitute, by pouring out dropwise the culture medium including a mixture of melanocytes and keratinocytes obtained in step f, or by 3D printing for example as described in Wonhye Lee et al. “Multi-layered culture of human skin fibroblasts and keratinocytes through three-dimensional freeform fabrication.” Biomaterials, 2009, March; 30(8):1587-95 [9].
In the presently disclosed subject matter, the seeding of the dermal substitute of step g can be advantageously carried out with a (keratinocytes+melanocytes)/fibroblasts ratio of 9 to 19. The present disclosure, in fact, demonstrates, surprisingly, that when the seeding of step g is carried out with a (keratinocytes+melanocytes)/fibroblasts ratio of 9 to 19, the skin substitute or skin equivalent obtained has structural/biological characteristics identical to those of normal skin.
In one embodiment, the seeding of the dermal substitute of step g is carried out with a (keratinocytes+melanocytes)/fibroblasts ratio of 9 to 19 and the matrix including collagen is a dermal regeneration matrix as defined above.
In the presently disclosed subject matter, the term “skin culture medium M5” is intended to mean any medium known to those with ordinary skill in the art that is suitable for the culture of skin. It can for example be a commercially available medium, for example a modified Green medium, namely including ⅔ of Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM); ⅓ of Ham's F12 medium and including 10% of fetal calf serum (FCS), which is a custom-made mixture sold by the company Gibco including in particular a mixture of amino acids, of vitamins, of inorganic salts and of sugars, for example glucose. It can also be a modified Green medium, that is to say a Green medium free of cholera toxin and of triodothyronine, or a mixture of Iscove's Modified Dulbecco's Medium (IMDM) and MCDB153 medium including 10% of FCS; or an IMDM/dermalife keratinocyte medium including 10% of FCS, sold respectively by the companies Gibco, Lifescience, Promocell and Sigma Aldrich.
In the presently disclosed subject matter, the medium M5 can likewise also include supplements chosen from hyaluronic acid or a hyaluronate or a derivative thereof, ascorbic acid or an ascorbate or a derivative thereof, or a mixture thereof.
In the presently disclosed subject matter, the medium M5 can include for example from 40 to 60 mg·L−1, from 45 to 55 mg·L−1, or 50 mg·L−1 of hyaluronate or hyaluronic acid.
Advantageously, when the medium M5 includes hyaluronic acid or a hyaluronate and/or a derivative thereof, it does not include bovine pituitary extract.
In the presently disclosed subject matter, the medium M5 can include for example from 40 to 60 mg·L−1, from 45 to 55 mg·L−1, or 50 mg·L−1 of ascorbic acid or ascorbate.
In the presently disclosed subject matter, the skin culture step h. can be carried out at a temperature included from 25 to 40° C., for example equal to 37° C.
In the presently disclosed subject matter, the skin culture time of step h. can be between 6 and 21 days, for example from 8 to 15 days.
In the presently disclosed subject matter, the skin culture of step h. can be carried out under a controlled atmosphere including at least 5% of CO2.
According to some embodiments, the skin culture of step h. can be carried out at a temperature included from 25 to 40° C., for example equal to 37° C. and under a controlled atmosphere including at least 5% of CO2.
In the presently disclosed subject matter, the medium M5 and/or each of the components thereof can be of clinical grade.
In the presently disclosed subject matter step h. can include:
The skin substitute culture medium M51 corresponds to the medium M5 as defined above including neither ascorbic acid nor ascorbate.
In the presently disclosed subject matter, the medium M51 and/or each of the components thereof can be of clinical grade.
The skin substitute or skin equivalent culture medium M52 corresponds to the medium M5 as defined above including hyaluronic acid or a hyaluronate or a derivative thereof, while at the same time being free of ascorbic acid or of ascorbate or a derivative thereof.
In the presently disclosed subject matter, the medium M52 can be a medium of clinical grade.
The skin substitute or skin equivalent culture medium M53 corresponds to the medium M5 as defined above including hyaluronic acid or a hyaluronate or a derivative thereof and ascorbic acid or ascorbate or a derivative thereof.
In the presently disclosed subject matter, the medium M53 can be a medium of clinical grade.
In the presently disclosed subject matter, the culture step h′ can be carried out by deposition in a culture medium M51 of the seeded dermal substitute obtained in step g.
In the presently disclosed subject matter, the culture step h′. can be carried out at a temperature included from 25 to 40° C., for example equal to 37° C.
In the presently disclosed subject matter, the duration of the culture step h′. can be from 6 to 24 hours, for example from 8 to 24 hours, or from 12 to 18 hours.
In the presently disclosed subject matter, the skin culture step h′. can be carried out under a controlled atmosphere including at least 5% of CO2.
Advantageously, the present disclosure demonstrates that step h′ makes it possible to promote the adhesion of the melanocytes and keratinocytes on the dermal substitute.
In the presently disclosed subject matter, the culture step h″ can be carried out by deposition in a culture medium M52 of the seeded dermal substitute obtained in step h′ or immersion or submersion of the seeded dermal substitute obtained in step h′ in a culture medium M52.
In the presently disclosed subject matter, the culture step h″. can be carried out at a temperature included from 25 to 40° C., for example equal to 37° C.
In the presently disclosed subject matter, the duration of the culture step h″. can be included from 0 to 7 days, preferably from 2 to 7 days.
In the presently disclosed subject matter, the skin culture step h″. can be carried out under controlled atmosphere including at least 5% of CO2
In the presently disclosed subject matter, the culture step h′″. can be carried out by a deposition in a culture medium M52 of the seeded dermal substitute obtained in step h″., immersion of the seeded dermal substitute obtained in step h″. in a culture medium M52, or immersion of the seeded dermal substitute obtained in step h″., the substitute being immersed in the medium up to the air-liquid interface, or so as to just break the surface of the medium.
In the presently disclosed subject matter, the term “breaking the surface of the medium” is intended to mean the immersion of the substitute in the medium in such a way as to cover the substitute over the entirety of its height without immersion of its upper part.
In the presently disclosed subject matter, the culture step h′″. can be carried out at a temperature included from 25 to 40° C., for example equal to 37° C.
In the presently disclosed subject matter, the duration of the culture step h″′. can be included from 2 to 7 days, preferably 7 days.
In the presently disclosed subject matter, the skin culture step h′″. can be carried out under a controlled atmosphere including at least 5% of CO2.
Advantageously, the present disclosure demonstrates that the immersion of the seeded dermal substitute obtained in step h″. in a culture medium M53 including hyaluronic acid or a hyaluronate or a derivative thereof and ascorbic acid or an ascorbate or a derivative thereof makes it possible to promote the formation of the dermal-epidermal junction and thus provides better polarization of the cells of the seeded dermal substitute.
Advantageously, the present disclosure also demonstrates that the immersion up to the air-liquid interface or just breaking the surface of the medium of the seeded dermal substitute obtained in step h″. in a culture medium M53 including hyaluronic acid or a hyaluronate or a derivative thereof and ascorbic acid or an ascorbate or a derivative thereof enables the epidermis to be differentiated, thus promoting the formation of a horny layer on the skin substitute or equivalent.
Advantageously, the present disclosure also demonstrates that the immersion up to the air-liquid interface or just breaking the surface of the medium of the seeded dermal substitute obtained in step h″ in a culture medium M53 including hyaluronic acid or a hyaluronate or a derivative thereof and ascorbic acid or an ascorbate or a derivative thereof makes it possible to maintain the high proliferative capacity of the cells of the basal layer and a decreasing gradient of proliferative capacity concomitant with the increase in differentiation of the epidermis similar to the gradients observed in the skin in vivo.
Advantageously, the present disclosure also demonstrates that, when the medium M5 includes hyaluronic acid or a hyaluronate or a derivative thereof, this makes it possible, surprisingly, to improve the quality of the skin substitute or equivalent including all or most of the layers forming the skins with a structure which is identical to that of the skin in vivo.
Advantageously, the present disclosure demonstrates that the method advantageously makes it possible to obtain a skin substitute or equivalent including all or most of the constituent layers thereof. Thus, the skin substitute obtained according to the method of some embodiments has characteristics similar to those of native skin, contrary to the skin substitutes known in the related art.
Advantageously, the present disclosure also demonstrates that the method makes it possible to obtain a dermal substitute and/or a skin substitute or equivalent that is much larger in size than those known in the related art. In particular, the method advantageously makes it possible to obtain a dermal substitute and/or a skin substitute or equivalent with a surface area of 1 to 25 cm2, for example of 5 to 25 cm2.
The present disclosure also advantageously demonstrates that the method makes it possible to obtain a dermal substitute or equivalent and/or a skin equivalent or substitute with a minimum amplification capacity of 6.
In addition, the present disclosure also advantageously demonstrates that the method makes it possible to obtain a dermal and/or skin equivalent that can be handled with viscoelastic properties that advantageously make it possible to avoid any tearing/physical alteration of the equivalent during handling thereof.
Advantageously, the present disclosure demonstrates that the skin equivalent includes melanocytes at the level of the basal stratum forming an epidermal melanization unit.
Advantageously, the skin equivalent that can be obtained by the abovementioned method advantageously exhibits constitutive pigmentation by virtue of the presence of melanocytes.
Another subject of the presently disclosed subject matter is the use of a skin equivalent according to some embodiments as laboratory tool.
In the presently disclosed subject matter, the term “laboratory tool” is intended to mean the use, for example of the skin equivalent, in in vitro tests. They can, for example, be tests having the object of studying the physiology, the structure, the evaluation of an agent, for example a pigmenting agent, a photoprotective agent or an antioxidant, on the skin equivalent.
In the presently disclosed subject matter and as mentioned above, the keratinocytes, melanocytes and fibroblasts present in the equivalent can independently result from different tissues/biopsies/cell cultures; thus, the skin equivalent can advantageously be representative of a pathology and/or allow the study of the influence of a group of cells, pathological or nonpathological, on the other groups of cells present in the equivalent. For example, the skin equivalent obtained can be representative and/or be a model of a skin pathology, for example juvenile acne, vitiligo, melasma, senile lentigo or scleroderma. In addition, advantageously, the skin equivalent obtained can represent or be a model of pathological skin, for example a model of carcinoma- or melanoma-type skin.
Consequently, another subject of the presently disclosed subject matter is the use of a skin equivalent in a process for evaluating at least one candidate agent.
In the presently disclosed subject matter, the candidate agent can be a candidate compound and/or an external agent.
According to some embodiments, the skin substitute can be used in any process for evaluating candidate compounds which is known to those with ordinary skill in the art and which are suitable for the evaluation of compounds with regard to the skin. For example, the skin equivalent can be used in the method described in publication document US 2004/0015149, in patent document U.S. Pat. No. 5,882,248, in document US 2008/0097607 or in document EP 2 781 191.
In use, the term “skin equivalent” is intended to mean a skin equivalent and/or substitute as mentioned above.
It can concern any chemical and/or biological compound known to those with ordinary skill in the art. It can concern, for example, a compound known to those with ordinary skill in the art and/or available commercially and/or a compound obtained by chemical synthesis or by extraction from plant, bacteria and/or yeast matter. It can concern, for example, a cosmetic compound or active principle, for example a cosmetic compound or active principle mentioned in the International Cosmetic Ingredient Dictionary and Handbook. It can also be a pharmaceutical and/or dermatological compound, for example any compound mentioned in the Merck Index and/or in the Orange Book.
In the presently disclosed subject matter, the term “external agent” is intended to mean, for example, ultraviolet (UV) radiation, infrared (IR) radiation, hypoxia, hyperoxia, foul air, for example having a high concentration of carbon dioxide and/or of nitrogen monoxide, and/or polluted air, for example town air.
In the presently disclosed subject matter, the evaluation process can also be a process of screening candidate compounds.
The evaluation process can include the stages of:
In the presently disclosed subject matter, the contacting stage can be carried out by any process known to those with ordinary skill in the art. It can, for example, be a direct application to a portion and/or the entirety of the surface of the skin equivalent, by dipping the skin equivalent in a solution including the agent, by any appropriate means known to those with ordinary skill in the art. Those with ordinary skill in the art, due to their general knowledge, will know how to adapt, as a function of the candidate compound, the stage of bringing into contact with the skin equivalent.
In the presently disclosed subject matter, the step of determining the effect can be carried out by any method known to those with ordinary skill in the art. It can, for example, be a comparison of the skin equivalent with a control skin equivalent which has not been brought into contact with the agent. It can, for example, be a visual observation of the macroscopic appearance of the skin equivalent or observation with an optical microscope of the skin equivalent, optionally subjected beforehand to staining or immunohistochemistry, for determination of melanin, damage to the DNA or epidermal differentiation. It can also be a proteomic or transcriptomic analysis of extracts of equivalents treated or not treated with agents.
Advantageously, the skin substitute is much larger in size than those known in the related art, allowing, in particular, concomitant evaluation of agents on one and the same equivalent.
Advantageously, the dermal equivalent includes at least one type I collagen matrix in which the fibroblasts are distributed. It can also contain other extracellular matrix constituents, for example molecules such as collagens, in particular collagen IV, laminins or glycosaminoglycans.
Other advantages can further emerge to those with ordinary skill in the art on reading the examples below, illustrated by the appended figures, given by way of illustration.
A few inventive aspects of the disclosed embodiments are explained in detail below with reference to the various figures. Exemplary embodiments are described to illustrate the disclosed subject matter, not to limit its scope, which is defined by the claims. Those of ordinary skill in the art will recognize a number of equivalent variations of the various features provided in the description that follows.
In the present example, the cells used came from a skin biopsy taken from mammoplasties previously carried out on a patient.
The biopsy was taken by a plastic surgeon and the biopsy was placed in a sterile tube containing physiological saline.
The cells were isolated from the biopsy as follows:
For the melanocytes, filtration, centrifugation at 1200 revolutions per minute and seeding of the pellet at 100 000 cells per cm2 in modified MCDB153 medium including the compounds mentioned in table 4 below, also including 5.88 g of sodium bicarbonate/5I, 0.272 g of tyrosine/5I and 0.157 g of L-methionine/5I, the pH of the medium being adjusted to 7.4.
In the present example, two skin equivalents obtained had (keratinocytes+melanocytes)/fibroblasts ratios of 13.3 respectively. For the ratio of 13.3, during the steps of depositing the fibroblasts and the keratinocytes/melanocytes mixture, the amounts of cells seeded were respectively 15 000 for the fibroblasts, 10 000 for the melanocytes and 190 000 for the keratinocytes.
Once the substitute/equivalent had been obtained, it was fixed in 4% formol, embedded in paraffin, then a 4 μm section was cut, and then hematoxylin-eosin staining was performed in order to label the various layers of the skin. Observation under an optical microscope and at a magnification of ×40 was carried out. Since the microscope was coupled to a CCD camera (Nikon, software NIS element Br), photographs of the observations were taken.
Moreover, immunohistochemical labeling of the equivalent obtained by the method in which the (keratinocytes+melanocytes)/fibroblasts ratio was 13.3 and of an in vivo skin was carried out according to the method described in Salducci, M., André, N., Guéré, C., Martin, M., Fitoussi, R., Vié, K., and Cario-André, M. (2014). Factors secreted by irradiated aged fibroblasts induce solar lentigo in pigmented reconstructed epidermis. Pigment Cell Melanoma Res. 27, 502-504 [12] or Simon, D., Daubos, A., Pain, C., Fitoussi, R., Vié, K., Taieb, A., de Benetti, L., and Cario-André, M. (2013). Exposure to acute electromagnetic radiation of mobile phone exposure range alters transiently skin homeostasis of a model of pigmented reconstructed epidermis. Int. J. Cosmet. Sci. 35, 27-34 [13] in order to identify in the equivalent the presence of melanocytes, the production of the basal lamina including in particular collagen IV (
As represented on these photographs, the skin substitute/equivalent obtained by the method has a structure identical to that of the skin in vivo.
| Number | Date | Country | Kind |
|---|---|---|---|
| 15305442.4 | Mar 2015 | EP | regional |
This application is a national phase filing under 35 C.F.R. § 371 of and claims priority to PCT Patent Application No. PCT/EP2016/056701, filed on Mar. 25, 2016, which claims the priority benefit under 35 U.S.C. § 119 of European Patent Application No. 15305442.4, filed on Mar. 26, 2015, the contents of each of which are hereby incorporated in their entireties by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2016/056701 | 3/25/2016 | WO | 00 |
